Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure (NCT07560982) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure
Italy300 participantsStarted 2026-07-01
Plain-language summary
A Prospective Observational, Multi-Center, Real-World Pharmacological Study Evaluating Adherence to Guideline-Directed Medical Therapy Using the Four-Pillar Strategy in Patients with Advanced Heart Failure
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \> 18 and \< 75 years
✓. Heart failure with left ventricular ejection fraction ≤ 35%
✓. Persistent symptoms of heart failure, New York Heart Association class III or IV
✓. Requirement for high-dose diuretic therapy, specifically Furosemide \> 50 mg/day orally as per routine clinical practice
✓. At least one of the following additional indicators of severity or refractoriness:
✓. need for progressive escalation of diuretics,
✓. intolerance to optimized medical therapy,
✓. persistence of symptoms despite advanced treatments such as (but not limited to) cardiac resynchronization therapy (CRT-D)and/or MitraClip
Exclusion criteria
✕. Age ≤ 18 years or ≥ 75 years
✕. Left ventricular ejection fraction \> 35%
✕. Mild or absent symptoms (New York Heart Association class I-II)
✕. Good response to optimized conventional guideline-directed medical therapy
✕. Extreme frailty or severe non-reversible disability, or psychiatric or cognitive disorders preventing adherence to follow-up
What they're measuring
1
assess the adherence to guideline-directed medical therapy in patients with advanced heart failure
Timeframe: 3 months, 6 months, 1 year, 2 years, 5 years